LEMTRADA (also known as Alemtuzumab)
Lemtrada is an antibody that binds to CD52, a molecule that is expressed on white blood cells. Lemtrada targets the problematic cells for destruction and is a powerful tool in a disease like multiple sclerosis (MS), which is thought to be caused by white blood cells attacking the central nervous system.
Patients with relapsing multiple sclerosis who have had inadequate responses to two or more medications for multiple sclerosis such as Interferon beta and Copaxone.
Patients with Human Immunodeficiency Virus should not be started on Lemtrada.
Lemtrada is recommended to be administered by intravenous infusion for 2 courses. The first course is 5 consecutive days of infusions and the second course is 3 consecutive days of infusions a year after the first course.